Opus Genetics (IRD) Stock Forecast & Price Target

Compare

1,233 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRD Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Opus

Genetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRD Stock 12 Month Forecast

Average Price Target

$8.00

▲(300.00% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Opus Genetics in the last 3 months. The average price target is $8.00 with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 300.00% change from the last price of $2.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.5384615384615383,3.0769230769230766,3.6153846153846154,4.153846153846153,4.692307692307692,5.230769230769231,5.769230769230769,6.3076923076923075,6.846153846153846,7.384615384615384,7.9230769230769225,8.461538461538462,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.4615384615384617,2.9230769230769234,3.3846153846153846,3.8461538461538463,4.307692307692308,4.769230769230769,5.230769230769231,5.6923076923076925,6.153846153846154,6.615384615384616,7.0769230769230775,7.538461538461538,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$9.00

Average Price Target$8.00

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Madison Elsaadi

B. Riley Securities

Buy

350.00%

Upside

Initiated

12/10/25

Opus Genetics initiated with a Buy at B. RileyOpus Genetics initiated with a Buy at B. Riley

Kumaraguru Raja

Brookline Capital Markets

Buy

300.00%

Upside

Initiated

12/01/25

Opus Genetics initiated with a Buy at BrooklineOpus Genetics initiated with a Buy at Brookline

Biren Amin

Piper Sandler

Buy

250.00%

Upside

Initiated

11/25/25

Analysts' Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)

Debanjana Chatterjee

JonesTrading

Buy

200.00%

Upside

Reiterated

11/20/25

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Bristol-Myers Squibb (NYSE: BMY) and PACS Group Inc (NYSE: PACS)

Matthew Caufield

H.C. Wainwright

Buy

300.00%

Upside

Reiterated

11/13/25

Promising Advancements in Opus Genetics' Retinal Disease Platform Support Buy Rating

James Molloy

Alliance Global Partners

Buy

350.00%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD) and Journey Medical Corp (NASDAQ: DERM)We aremaintaining our Buy räng and $9 price target.

Yun Zhong

Wedbush

Buy

300.00%

Upside

Reiterated

11/12/25

Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

11/06/25

Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Opus Genetics (IRD)

Daniil Gataulin

Chardan Capital

Buy

350.00%

Upside

Initiated

10/16/25

Opus Genetics initiated with a Buy at ChardanOpus Genetics initiated with a Buy at Chardan

Dev Prasad

Lucid Capital

Buy

150.00%

Upside

Initiated

06/17/25

Opus Genetics initiated with a Buy at Lucid CapitalOpus Genetics initiated with a Buy at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Madison Elsaadi

B. Riley Securities

Buy

350.00%

Upside

Initiated

12/10/25

Opus Genetics initiated with a Buy at B. RileyOpus Genetics initiated with a Buy at B. Riley

Kumaraguru Raja

Brookline Capital Markets

Buy

300.00%

Upside

Initiated

12/01/25

Opus Genetics initiated with a Buy at BrooklineOpus Genetics initiated with a Buy at Brookline

Biren Amin

Piper Sandler

Buy

250.00%

Upside

Initiated

11/25/25

Analysts' Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD)

Debanjana Chatterjee

JonesTrading

Buy

200.00%

Upside

Reiterated

11/20/25

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Bristol-Myers Squibb (NYSE: BMY) and PACS Group Inc (NYSE: PACS)

Matthew Caufield

H.C. Wainwright

Buy

300.00%

Upside

Reiterated

11/13/25

Promising Advancements in Opus Genetics' Retinal Disease Platform Support Buy Rating

James Molloy

Alliance Global Partners

Buy

350.00%

Upside

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD) and Journey Medical Corp (NASDAQ: DERM)We aremaintaining our Buy räng and $9 price target.

Yun Zhong

Wedbush

Buy

300.00%

Upside

Reiterated

11/12/25

Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

11/06/25

Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Opus Genetics (IRD)

Daniil Gataulin

Chardan Capital

Buy

350.00%

Upside

Initiated

10/16/25

Opus Genetics initiated with a Buy at ChardanOpus Genetics initiated with a Buy at Chardan

Dev Prasad

Lucid Capital

Buy

150.00%

Upside

Initiated

06/17/25

Opus Genetics initiated with a Buy at Lucid CapitalOpus Genetics initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Opus Genetics

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+9.52%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +9.52% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+20.05%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +20.05% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

10/11 ratings generated profit

Average Return

+61.25%

reiterated a buy rating last month

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +61.25% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+65.47%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +65.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRD Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRD has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRD average Analyst price target in the past 3 months is 8.00.

Each month's total comprises the sum of three months' worth of ratings.

IRD Financial Forecast

IRD Earnings Forecast

The previous quarter’s earnings for IRD were -$0.25.

IRD Sales Forecast

The previous quarter’s earnings for IRD were $3.08M.

IRD Stock Forecast FAQ

What is IRD’s average 12-month price target, according to analysts?

Based on analyst ratings, Opus Genetics’s 12-month average price target is 8.00.

What is IRD’s upside potential, based on the analysts’ average price target?

Opus Genetics has 300.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRD a Buy, Sell or Hold?

Opus Genetics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Opus Genetics’s price target?

The average price target for Opus Genetics is 8.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $6.00. The average price target represents 300.00% Increase from the current price of $2.

What do analysts say about Opus Genetics?

Opus Genetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of IRD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Opus Genetics (IRD) Stock Forecast & Price Target

IRD Analyst Ratings

IRD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Opus Genetics

IRD Analyst Recommendation Trends

IRD Financial Forecast

IRD Earnings Forecast

IRD Sales Forecast

IRD Stock Forecast FAQ

Detailed List of Analyst Forecasts